Xencor has begun the Phase 1 clinical trial of humanised monoclonal antibody XmAb5871 for the treatment of autoimmune diseases.

XmAb5871 uses a selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (FcyRIIb), and is designed to help in the suppression of autoimmune response.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Preclinical studies demonstrated that XmAb5871 suppresses autoimmune response in humanised mouse models of systemic lupus erythematosus, without the depletion of B cells.

The study results suggest that XmAb5871 could be an effective immunosuppressant in multiple indications, including lupus and rheumatoid arthritis.

The endpoints of the Phase I study include safety, pharmacokinetics and a number of biomarkers of immunomodulatory drug activity.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact